-
GSK receives FDA OK for new Jemperli indication
Jemperli is now also indicated to treat patients with recurrent or advanced mismatch repair-deficient endometrial cancer. -
Gilead’s Trodelvy receives FDA nod for new indication
Trodelvy is now approved for pre-treated HR+/HER2- metastatic breast cancer.